Logo Envista Holdings

Envista Holdings (NVST) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Envista Holdings · Health Care · ref. ETF XLV · 53 calls · price $22.65
🔔Price alertsCreate an alert →
What the company does: Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally.

📈 Envista Holdings (NVST) stock price

$22.65+16.5% over range
Oct 14, 25low $18.95 · high $30.26Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
44% recommend buying · 9 analysts
📊 JPI status : Envista Holdings has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 NVST price target & analyst consensus — price $22.65

The price target · all analysts combined (9 targets)
Highest target · 1 firm of 9$33+45.7%
Median target · of 9 targets$29+28.0%
Lowest target · 1 firm of 9$21-7.3%
Current price$22.65
Where these 9 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 889% $26 ↔ $33
Below 111% $21
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 64% of its targets hit on this sector (124 calls tested). It aims for $27 (+19 %), call made on September 19, 2026, maturing on September 19, 2027 (25 d ago).

The 2 reliable analysts $29.50+30 %
The 7 other firms $29+28 %
How to read it: the 2 reliable firms are not filtered by optimism — 2 aim above the price, 0 below, hence their $29.50 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 9 ratings (last 6 months)
Strong Buy00%
Buy444%
Hold556%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Envista Holdings? The JPI assistant answers using our backtest data.

📈 Envista Holdings fundamentals: valuation, margins & growth › open the full page

P/E 39.1Net margin 3.3 %Revenue growth +7.1 %Cheap for the growth

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 9 %
2023
Rev −0%Profit −141%
2024
Rev −2%
2025
Rev +8%

🔎 Detailed analyses

✅ Historical analyst reliability on NVST

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Evercore ISI Group ↗ 100% +19.3% 4
Credit Suisse 75% +15.1% 4
Baird ↗ 67% +67.0% 3
B of A Securities ↗ 50% +5.8% 4
Stifel ↗ 50% +5.5% 6
Mizuho ↗ 50% -15.8% 2
JP Morgan ↗ 40% +60.5% 5
Goldman Sachs ↗ 25% -3.5% 4
Morgan Stanley ↗ 0% -19.5% 9
Piper Sandler ↗ 0% -26.8% 4

📊 What $1,000 invested in Envista Holdings would be worth › open the full page

In short — $1,000 invested in Envista Holdings 10 years ago would be worth $916 today, i.e. -1%/yr on average. Best year: 2021 (+34%), worst: 2023 (-29%). Price performance, excluding dividends.

If I'd invested $1,000 in Envista Holdings

InvestmentWorth todayGain
1 years ago$1,385+38%
3 years ago$783-22%
5 years ago$781-22%
→ See Envista Holdings's full return history + gain calculator

Return by year (Envista Holdings)

YearReturn$1,000 invested at year start
2026 (YTD)+21%$1,215 (+21%)
2025+14%$1,385 (+38%)
2024-21%$1,095 (+10%)
→ See Envista Holdings's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Envista Holdings

Loading news…

📋 All analyst calls on NVST

Piper Sandler ↗
Oct 9, 26
■ Neutral neutral · not a buy · 🎯$26
Price at call : $22.72 — gap to target +14%
Today : $22.65 — gap to target +15%
🎯 on NVST : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Oct 9, 27
BMO Capital ↗
Sep 28, 26
■ Market Perform neutral · not a buy · 🎯$26
Price at call : $23.33 — gap to target +11%
Today : $22.65 — gap to target +15%
🎯 on NVST : no call matured yet · 📊 on Health : 45.7% · +6.4% (35 calls)
in progress (365j)
matures : Sep 28, 27
Piper Sandler ↗
Sep 18, 26
■ Neutral neutral · not a buy · 🎯$28
Price at call : $23.43 — gap to target +20%
Today : $22.65 — gap to target +24%
🎯 on NVST : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Sep 18, 27
UBS ↗
Sep 18, 26
■ Neutral neutral · not a buy · 🎯$27
Price at call : $23.43 — gap to target +15%
Today : $22.65 — gap to target +19%
🎯 on NVST : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Sep 18, 27
Needham ↗
Sep 18, 26
■ Hold neutral · not a buy
🎯 on NVST : no call matured yet · 📊 on Health : 47.2% · +2.5% (142 calls)
in progress (365j)
matures : Sep 18, 27
JP Morgan ↗
Sep 3, 26
▲ Overweight · 🎯$32
Price at call : $27.28 — upside +17%
Today : $22.65 — upside +41%
🎯 on NVST : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Sep 3, 27
Piper Sandler ↗
Aug 6, 26
■ Neutral neutral · not a buy · 🎯$28
Price at call : $28.15 — gap to target -1%
Today : $22.65 — gap to target +24%
🎯 on NVST : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Aug 6, 27
Piper Sandler ↗
Jul 29, 26
■ Neutral neutral · not a buy · 🎯$26
Price at call : $27.78 — gap to target -6%
Today : $22.65 — gap to target +15%
🎯 on NVST : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Jul 29, 27
See the other 45 calls, newest to oldest
BMO Capital ↗
Jul 9, 26
■ Market Perform neutral · not a buy · 🎯$27
Price at call : $25.91 — gap to target +4%
Today : $22.65 — gap to target +19%
🎯 on NVST : no call matured yet · 📊 on Health : 45.7% · +6.4% (35 calls)
in progress (365j)
matures : Jul 9, 27
Barclays ↗
Jun 11, 26
▲ Overweight · 🎯$32
Price at call : $24.6 — upside +30%
Today : $22.65 — upside +41%
🎯 on NVST : no call matured yet · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Jun 11, 27
JP Morgan ↗
May 7, 26
■ Neutral neutral · not a buy · 🎯$29
Price at call : $24.24 — gap to target +20%
Today : $22.65 — gap to target +28%
🎯 on NVST : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : May 7, 27
▲ Outperform · 🎯$33
Price at call : $24.24 — upside +36%
Today : $22.65 — upside +46%
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : May 7, 27
Baird ↗
May 7, 26
▲ Outperform · 🎯$31
Price at call : $24.29 — upside +28%
Today : $22.65 — upside +37%
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 48.1% · +0.7% (77 calls)
in progress (365j)
matures : May 7, 27
Morgan Stanley ↗
Apr 24, 26
■ Equal-Weight neutral · not a buy · 🎯$21
Price at call : $26.8 — gap to target -22%
Today : $22.65 — gap to target -7%
🎯 on NVST : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Apr 24, 27
Citigroup ↗
Apr 15, 26
■ Neutral neutral · not a buy · 🎯$29
Price at call : $26.94 — gap to target +8%
Today : $22.65 — gap to target +28%
🎯 on NVST : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Apr 15, 27
▲ Outperform · 🎯$30
Price at call : $26.67 — upside +12%
Today : $22.65 — upside +32%
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : Apr 8, 27
Barclays ↗
Feb 11, 26
▲ Overweight · 🎯$34
Price at call : $30.26 — upside +12%
Today : $22.65 — upside +50%
🎯 on NVST : no call matured yet · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Feb 11, 27
Mizuho ↗
Feb 10, 26
■ Neutral neutral · not a buy · 🎯$27
Price at call : $30.17 — gap to target -11%
Today : $22.65 — gap to target +19%
🎯 on NVST : 0% (1 call matured) · 📊 on Health : 57.1% · +12.3% (70 calls)
in progress (365j)
matures : Feb 10, 27
JP Morgan ↗
Feb 6, 26
■ Neutral neutral · not a buy · 🎯$26
Price at call : $29.36 — gap to target -11%
Today : $22.65 — gap to target +15%
🎯 on NVST : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Feb 6, 27
Stifel ↗
Feb 6, 26
▲ Buy · 🎯$31
Price at call : $29.36 — upside +6%
Today : $22.65 — upside +37%
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 48% · +12.3% (100 calls)
in progress (365j)
matures : Feb 6, 27
Wells Fargo ↗
Feb 6, 26
■ Equal-Weight neutral · not a buy · 🎯$26
Price at call : $29.36 — gap to target -11%
Today : $22.65 — gap to target +15%
🎯 on NVST : no call matured yet · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Feb 6, 27
Piper Sandler ↗
Feb 6, 26
■ Neutral neutral · not a buy · 🎯$25
Price at call : $29.36 — gap to target -15%
Today : $22.65 — gap to target +10%
🎯 on NVST : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Feb 6, 27
Stifel ↗
Feb 4, 26
▲ Buy · 🎯$27
Price at call : $23.66 — upside +14%
Today : $22.65 — upside +19%
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 48% · +12.3% (100 calls)
in progress (365j)
matures : Feb 4, 27
UBS ↗
Feb 3, 26
■ Neutral neutral · not a buy · 🎯$25
Price at call : $22.91 — gap to target +9%
Today : $22.65 — gap to target +10%
🎯 on NVST : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Feb 3, 27
Piper Sandler ↗
Jan 30, 26
■ Neutral neutral · not a buy · 🎯$21
Price at call : $23.26 — gap to target -10%
Today : $22.65 — gap to target -7%
🎯 on NVST : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Jan 30, 27
Mizuho ↗
Jan 20, 26
■ Neutral neutral · not a buy · 🎯$24
Price at call : $24.34 — gap to target -1%
Today : $22.65 — gap to target +6%
🎯 on NVST : 0% (1 call matured) · 📊 on Health : 57.1% · +12.3% (70 calls)
in progress (365j)
matures : Jan 20, 27
JP Morgan ↗
Dec 16, 25
■ Neutral neutral · not a buy · 🎯$22
Price at call : $21.85 — gap to target +1%
Today : $22.65 — gap to target -3%
🎯 on NVST : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Dec 16, 26
Barclays ↗
Dec 9, 25
▲ Overweight · 🎯$24
Price at call : $22.1 — upside +9%
Today : $22.65 — upside +6%
🎯 on NVST : no call matured yet · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Dec 9, 26
Mizuho ↗
Aug 1, 25
▼ Underperform · 🎯$18
Price at call : $20.48 — upside -12%
Today : $22.65 — upside -21%
Expected -12% · Actual +34% · Reason (≤ −15%) : ✗ No
🎯 on NVST : 0% (1 call matured) · 📊 on Health : 57.1% · +12.3% (70 calls)
-33.6%
stock +34% · XLV +22%
matured Aug 1, 26
Stifel ↗
Aug 1, 25
▲ Buy · 🎯$25
Price at call : $20.48 — upside +22%
Today : $22.65 — upside +10%
Expected +22% · Actual +34% · Reason (≥ +15%) : ✓ Yes
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 48% · +12.3% (100 calls)
+33.6%
stock +34% · XLV +22%
matured Aug 1, 26
■ Equal-Weight neutral · not a buy · 🎯$17
Price at call : $20.48 — gap to target -17%
Today : $22.65 — gap to target -25%
🎯 on NVST : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Aug 1, 26
Wells Fargo ↗
Aug 1, 25
■ Equal-Weight neutral · not a buy · 🎯$19
Price at call : $20.48 — gap to target -7%
Today : $22.65 — gap to target -16%
🎯 on NVST : no call matured yet · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Aug 1, 26
Piper Sandler ↗
Aug 1, 25
■ Neutral neutral · not a buy · 🎯$19
Price at call : $20.83 — gap to target -9%
Today : $22.65 — gap to target -16%
🎯 on NVST : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Aug 1, 26
UBS ↗
Jul 29, 25
■ Neutral neutral · not a buy · 🎯$22
Price at call : $19.96 — gap to target +10%
Today : $22.65 — gap to target -3%
🎯 on NVST : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Jul 29, 26
▲ Outperform · 🎯$23
Price at call : $20.38 — upside +13%
Today : $22.65 — upside +2%
Expected +13% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 39.1% · -4.9% (46 calls)
+26.4%
stock +26% · XLV +20%
matured Jul 9, 26
Baird ↗
May 27, 25
▲ Outperform · 🎯$23
Price at call : $18.53 — upside +24%
Today : $22.65 — upside +2%
Expected +24% · Actual +28% · Reason (≥ +15%) : ✓ Yes
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 48.1% · +0.7% (77 calls)
+27.7%
stock +28% · XLV +15%
matured May 27, 26
UBS ↗
May 5, 25
■ Neutral neutral · not a buy · 🎯$18
Price at call : $16.39 — gap to target +10%
Today : $22.65 — gap to target -21%
🎯 on NVST : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : May 5, 26
Baird ↗
May 2, 25
■ Neutral neutral · not a buy · 🎯$21
Price at call : $16.99 — gap to target +24%
Today : $22.65 — gap to target -7%
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 48.1% · +0.7% (77 calls)
in progress (365j)
matures : May 2, 26
Piper Sandler ↗
Apr 30, 25
■ Neutral neutral · not a buy · 🎯$17
Price at call : $16.34 — gap to target +4%
Today : $22.65 — gap to target -25%
🎯 on NVST : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Apr 30, 26
▲ Buy · 🎯$23
Price at call : $16.08 — upside +43%
Today : $22.65 — upside +2%
Expected +43% · Actual +61% · Reason (≥ +15%) : ✓ Yes
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 64.2% · +20.2% (109 calls)
+61.3%
stock +61% · XLV +4%
matured Apr 29, 26
UBS ↗
Mar 10, 25
■ Neutral neutral · not a buy · 🎯$21
Price at call : $17.13 — gap to target +23%
Today : $22.65 — gap to target -7%
🎯 on NVST : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Mar 10, 26
JP Morgan ↗
Mar 6, 25
■ Neutral neutral · not a buy · 🎯$19
Price at call : $18.43 — gap to target +3%
Today : $22.65 — gap to target -16%
🎯 on NVST : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Mar 6, 26
■ Equal-Weight neutral · not a buy · 🎯$19
Price at call : $17.83 — gap to target +7%
Today : $22.65 — gap to target -16%
🎯 on NVST : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Mar 6, 26
Needham ↗
Mar 6, 25
■ Hold neutral · not a buy
🎯 on NVST : no call matured yet · 📊 on Health : 47.2% · +2.5% (142 calls)
in progress (365j)
matures : Mar 6, 26
Needham ↗
Feb 25, 25
■ Hold neutral · not a buy
🎯 on NVST : no call matured yet · 📊 on Health : 47.2% · +2.5% (142 calls)
in progress (365j)
matures : Feb 25, 26
Wells Fargo ↗
Feb 6, 25
■ Equal-Weight neutral · not a buy · 🎯$21
Price at call : $21.25 — gap to target -1%
Today : $22.65 — gap to target -7%
🎯 on NVST : no call matured yet · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Feb 6, 26
Baird ↗
Feb 6, 25
■ Neutral neutral · not a buy · 🎯$23
Price at call : $21.79 — gap to target +6%
Today : $22.65 — gap to target +2%
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 48.1% · +0.7% (77 calls)
in progress (365j)
matures : Feb 6, 26
■ Equal-Weight neutral · not a buy · 🎯$20
Price at call : $21.79 — gap to target -8%
Today : $22.65 — gap to target -12%
🎯 on NVST : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Feb 6, 26
Needham ↗
Feb 6, 25
■ Hold neutral · not a buy
🎯 on NVST : no call matured yet · 📊 on Health : 47.2% · +2.5% (142 calls)
in progress (365j)
matures : Feb 6, 26
Piper Sandler ↗
Feb 3, 25
■ Neutral neutral · not a buy · 🎯$18
Price at call : $20.13 — gap to target -11%
Today : $22.65 — gap to target -21%
🎯 on NVST : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Feb 3, 26
■ Market Perform neutral · not a buy · 🎯$23
Price at call : $20.97 — gap to target +10%
Today : $22.65 — gap to target +2%
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 58.3% · +20.9% (12 calls)
in progress (365j)
matures : Oct 31, 25
▼ Underperform · 🎯$19
Price at call : $21.92 — upside -13%
Today : $22.65 — upside -16%
Expected -13% · Actual -6% · Reason (≤ −15%) : ✗ No
🎯 on NVST : 100% (1 call matured) · 📊 on Health : 58.3% · +20.9% (12 calls)
+5.8%
stock -6% · XLV +1%
matured Feb 25, 25
William Blair ↗
Feb 8, 24
■ Market Perform neutral · not a buy
🎯 on NVST : no call matured yet · 📊 on Health : 50% · +37.8% (20 calls)
in progress (365j)
matures : Feb 7, 25

Frequently asked questions

Should I buy Envista Holdings stock?

This isn't buy advice. For Envista Holdings, the analyst consensus is "Hold", with an average price target of $29.00 (+28% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (4 calls tracked on Envista Holdings). We show the numbers — you decide.

Is it too late to buy Envista Holdings? How high can it go?

The most bullish analyst target on Envista Holdings is $33.00 (+46% above today's price); the average is $29.00. That's the upside they see. Check how reliable those analysts have actually been on Envista Holdings on our site before trusting it.

Is Envista Holdings still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 10 analysts have a real record on Envista Holdings, the best hitting 100% over 4 calls. Current consensus: "Hold". Make your call on data, not noise.

Should you invest in Envista Holdings? The case for and against

The arguments for and against, one by one, from the numbers: why invest in NVST (and why hesitate).

What has Envista Holdings's past performance been?

Historical returns and a "how much if I had invested" calculator: NVST performance & returns.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)